DSIP is a prescription therapy used for sleep support.

Patients seeking support for sleep support may qualify after evaluation by a licensed provider.

Yes. DSIP is a compounded prescription medication. A telehealth consultation and medical intake are required before dispensing to ensure this formulation is appropriate for your health history, goals, and current medications.

DSIP is generally well-tolerated. Some patients report mild drowsiness shortly after administration, which is expected given the timing of use. No significant adverse effects have been established at therapeutic doses. Individual responses vary — report any unusual or persistent symptoms to your provider.

DSIP is not indicated for patients who are pregnant or breastfeeding. Patients with significant hepatic or renal impairment require individualized dosing review. Disclose your complete medical history and current medications before starting treatment.

Formal drug interaction studies for DSIP have not been conducted. Based on its mechanism of action — HPA axis modulation, cortisol suppression, and serotonergic and noradrenergic system modulation - patients should disclose the following to their provider before starting treatment: CNS depressants and sleep medications (benzodiazepines, zolpidem, opioids), as additive sedative effects are possible even when mechanisms differ; corticosteroids (prednisone, hydrocortisone, dexamethasone), as DSIP suppresses CRH and ACTH and may alter HPA axis dynamics in patients on exogenous steroids; antidepressants including SSRIs, SNRIs, and MAOIs, which share serotonergic and noradrenergic targets with DSIP; and beta-blockers, which independently suppress melatonin and alter sleep architecture. Alcohol directly suppresses delta wave sleep and will counteract DSIP's primary mechanism — concurrent use on nights of administration is not recommended. DSIP is generally compatible with other peptide protocols; when combined with Sermorelin or Pinealon, additive sleep-promoting effects may be therapeutically desirable under provider supervision. Always provide a complete medication and supplement list before beginning treatment.

DSIP is generally well-tolerated when prescribed and dosed appropriately by a licensed provider. However, certain pre-existing conditions require individualized evaluation before starting treatment. Patients with HPA axis disorders — including Cushing's syndrome, Addison's disease, or adrenal insufficiency — require careful provider review, as DSIP modulates CRH and cortisol output and may alter hormonal dynamics in patients with pre-existing adrenal or pituitary dysfunction. Patients with major depressive disorder, generalized anxiety disorder, or PTSD may benefit significantly from DSIP's cortisol-lowering and sleep-deepening effects, but should disclose all psychiatric medications before starting, as DSIP modulates serotonergic and noradrenergic signaling. Patients with cardiovascular disease or hypertension should inform their provider, as cortisol reduction and improved sleep architecture can influence blood pressure regulation and cardiac recovery. Patients with significant hepatic or renal impairment require individualized dosing review, as metabolic clearance may be altered. DSIP is not indicated for patients who are pregnant or breastfeeding, as safety data in these populations is insufficient. Patients with a history of malignancy should disclose this before starting, and treatment will be determined at provider discretion. This formulation is not indicated for patients under 18. Your provider requires a complete medical history before prescribing — disclose all conditions, medications, and supplements at the time of your intake.